Becton, Dickinson and Company (NYSE:BDX) Position Raised by CIBC Asset Management Inc

CIBC Asset Management Inc increased its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 56,923 shares of the medical instruments supplier's stock after buying an additional 2,824 shares during the quarter. CIBC Asset Management Inc's holdings in Becton, Dickinson and Company were worth $13,717,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its stake in shares of Becton, Dickinson and Company by 6.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier's stock valued at $1,181,483,000 after acquiring an additional 302,893 shares during the period. Massachusetts Financial Services Co. MA raised its position in Becton, Dickinson and Company by 1.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier's stock valued at $1,146,374,000 after purchasing an additional 87,230 shares during the period. Bank of New York Mellon Corp raised its position in Becton, Dickinson and Company by 8.5% in the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier's stock valued at $1,031,167,000 after purchasing an additional 346,720 shares during the period. Clearbridge Investments LLC lifted its stake in shares of Becton, Dickinson and Company by 3.1% during the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier's stock worth $697,513,000 after purchasing an additional 89,157 shares in the last quarter. Finally, First Eagle Investment Management LLC boosted its position in shares of Becton, Dickinson and Company by 32.5% in the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier's stock worth $655,149,000 after buying an additional 688,296 shares during the period. Hedge funds and other institutional investors own 86.97% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on BDX shares. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an "outperform" rating for the company in a research report on Friday, August 2nd. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Citigroup upgraded Becton, Dickinson and Company from a "neutral" rating to a "buy" rating and raised their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Finally, StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Thursday, August 8th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $283.00.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $2.02 during trading hours on Friday, reaching $225.15. 1,965,697 shares of the stock were exchanged, compared to its average volume of 1,528,964. The stock has a market capitalization of $65.08 billion, a P/E ratio of 37.90, a P/E/G ratio of 1.68 and a beta of 0.43. The firm has a 50 day simple moving average of $236.30 and a 200-day simple moving average of $234.99. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. During the same period last year, the business posted $3.42 earnings per share. The firm's revenue for the quarter was up 6.9% on a year-over-year basis. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a $1.04 dividend. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. This is a boost from Becton, Dickinson and Company's previous quarterly dividend of $0.95. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.